Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
Real-time Estimate Cboe BZX  -  03:13:50 2023-01-27 pm EST
140.25 USD   +0.40%
12:14aInsider Sell: Seagen
MT
01/25Berenberg Adjusts Price Target on Seagen to $170 From $183, Maintains Buy Rating
MT
01/20SVB Securities Adjusts Price Target on Seagen to $162 From $160, Maintains Outperform Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

All news about SEAGEN INC.
12:14aInsider Sell: Seagen
MT
01/25Berenberg Adjusts Price Target on Seagen to $170 From $183, Maintains Buy Rating
MT
01/20SVB Securities Adjusts Price Target on Seagen to $162 From $160, Maintains Outperform R..
MT
01/19Seagen Inc. : Other Events (form 8-K)
AQ
01/19Seagen Gets FDA Accelerated Approval for Colorectal Cancer Drug Tukysa
MT
01/19Seagen Gets FDA Accelerated Approval for Tukysa
DJ
01/19US FDA Grants Approval to Seagen's Tukysa to Treat Colorectal Cancer
MT
01/19Seagen Announces FDA Accelerated Approval of TUKYSA® (tucatinib) in Combination with Tr..
BU
01/19Seagen Inc. Announces FDA Approval of Tukysa in Combination with Trastuzumab for People..
CI
01/19Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2..
BU
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 914 M - -
Net income 2022 -656 M - -
Net cash 2022 1 374 M - -
P/E ratio 2022 -39,6x
Yield 2022 -
Capitalization 25 936 M 25 936 M -
EV / Sales 2022 12,8x
EV / Sales 2023 10,5x
Nbr of Employees 2 675
Free-Float 98,9%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 139,69 $
Average target price 160,67 $
Spread / Average Target 15,0%
EPS Revisions
Managers and Directors
David R. Epstein Chief Executive Officer & Director
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.8.70%25 936
MODERNA, INC.7.49%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-3.63%28 492
CELLTRION, INC.3.93%19 184